Compare ESP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | SKYE |
|---|---|---|
| Founded | 1928 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 44.9M |
| IPO Year | N/A | N/A |
| Metric | ESP | SKYE |
|---|---|---|
| Price | $47.00 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 14.9K | ★ 494.0K |
| Earning Date | 02-11-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $42,600,530.00 | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $14.83 | ★ N/A |
| Revenue Growth | ★ 4.90 | N/A |
| 52 Week Low | $24.85 | $0.68 |
| 52 Week High | $55.00 | $5.75 |
| Indicator | ESP | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 66.01 | 38.82 |
| Support Level | $46.27 | $0.68 |
| Resistance Level | $47.77 | $0.95 |
| Average True Range (ATR) | 1.37 | 0.11 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 81.68 | 38.81 |
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.